POLYMED
Poly Medicure
Each stock's 10,000-path forecast, rendered as light.
Poly Medicure (POLYMED) Stock Analysis & Case Study
Is POLYMED a good buy? The data-driven verdict.
Poly Medicure (POLYMED) trades at ₹1,671,on the numbers it high-risk on the numbers, a Downstox Snapshot Score of 27/100.
On the numbers, Poly Medicure (POLYMED) high-risk on the numbers, a Downstox Snapshot Score of 27/100, weighing expensive at 51.8× earnings, ROE of 11.2%, a 29% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
POLYMED fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is POLYMED overvalued? POLYMED P/E vs its sector
POLYMED's P/E of 51.8× sits above the sector peer median of 15.9×, so on earnings it screens richer than peers, while its 0.21% dividend yield is below the peer median of 1.65%.
POLYMED share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of POLYMED history (-14%/yr drift, 44%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| POLYMED 2027 | ₹714 | ₹1,234 | ₹2,137 | -21% |
| POLYMED 2028 | ₹433 | ₹972 | ₹2,130 | -38% |
| POLYMED 2029 | ₹292 | ₹766 | ₹2,037 | -51% |
| POLYMED 2030 | ₹198 | ₹609 | ₹1,888 | -61% |
| POLYMED 2031 | ₹139 | ₹482 | ₹1,687 | -69% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability POLYMED goes up, or doubles?
The bull case for POLYMED
- Poly Medicure is part of the nifty200 universe with live, tracked fundamentals on Downstox.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹2,037.
The bear case & risks
- A rich 51.8× P/E leaves a thin margin of safety if growth slows.
- Return on equity is a soft 11.2%, capital efficiency trails higher-quality peers.
- The probability model is cautious 12 months out, only a 29% chance of finishing above today's price.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹292.
POLYMED volatility & expected range, how bumpy is the ride?
Over the last 2.0 years POLYMED compounded at -14%/year with annualized volatility of 44%. That volatility implies a 1-year 80% range of ₹714–₹2,137, the honest backbone behind any single price target.
POLYMED price forecast, the full 60-month probability fan
POLYMED price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds POLYMED hits common targets within the simulated horizon?
Full multi-horizon detail on the POLYMED price target & forecast page.
POLYMED Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. POLYMED scores 4/9,mixed financial health.
POLYMED MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy POLYMED with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| UpstoxCHEAPEST | 35.7% | 2.8× |
| ZerodhaCHEAPEST | 35.7% | 2.8× |
| DhanCHEAPEST | 35.7% | 2.8× |
Compare every broker on the POLYMED MTF page.
POLYMED vs peers,sector comparison
About Poly Medicure: sector, index & market-cap context
Poly Medicure (POLYMED) is a small-cap NSE-listed company, and a constituent of the Nifty 200 index group, with a market capitalisation of ₹16,949 Cr. See more Nifty 200 stocks.
How the POLYMED Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Poly Medicure's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
POLYMED analysis, FAQs
Is Poly Medicure (POLYMED) a good buy?
On the numbers, Poly Medicure (POLYMED) high-risk on the numbers, a Downstox Snapshot Score of 27/100, weighing expensive at 51.8× earnings, ROE of 11.2%, a 29% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is POLYMED overvalued or undervalued?
POLYMED trades at 51.8× earnings versus a peer median of 15.9×, so it screens richer than its sector peers.
What is the POLYMED share price target for 2031?
POLYMED's probability-weighted 2031 median target is ₹482, with an 80% range of ₹139–₹1,687 (10,000-path Monte-Carlo).
What is the probability POLYMED doubles in 5 years?
The modelled probability of POLYMED reaching ₹3,127 (2×) within 5 years is 3%.
What is the bull case for POLYMED?
Poly Medicure is part of the nifty200 universe with live, tracked fundamentals on Downstox.
What are the risks in POLYMED?
A rich 51.8× P/E leaves a thin margin of safety if growth slows. Return on equity is a soft 11.2%, capital efficiency trails higher-quality peers. The probability model is cautious 12 months out, only a 29% chance of finishing above today's price.